The peptide synthesis market is projected to secure a valuation of USD 520.0 million in 2023 and is rising to USD 1.1 billion by 2033. The market is predicted at a CAGR of 8% during the forecast period.
Peptide Synthesis Market – Driving Factors
Increasing Medication Issues Decline Market Growth
Rising chemical-produced medications and regulatory issues are the factors that may restrain market growth. The European Medicines Agency and Food and Drug Administration are also at odds in regulating the approval of medications based on the peptide. The lack of consistent rules and difficulty in permitting therapeutic peptides limit market growth.
How do Peptide Synthesis Manufacturers Drive Market Opportunities?
Advanced medicine and limited side effects increase the demand for peptide synthesis and market opportunities during the forecast period. The growing investment and key healthcare manufacturers pushing the investment in personalized medicine are driving market expansion.
Growing technology of automated injection of various chemicals, such as membrane enhanced and ligand synthesis, is increasing the adoption of peptide synthesis.
Growing healthcare infrastructure and improvements in medications are boosting market opportunities. Manufacturers are advancing customized medicine, and individualized therapy for patients is further increasing market opportunities. The development of proteomic analysis and methods of determining molecular profiles greatly contribute to expanding the market growth.
The adoption of proteomics to clarify pathomechanisms illness is propelling the market size. The European Union scientist announced the development of user-friendly electrochemical customized peptide synthesis in the ElectroMed project, a technology to detect the interaction between immune receptors and short peptides. This customized peptide synthesis is typically based on a microfluidic multiplexing system.
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 8% |
| Market Valuation (2023) | USD 520 million |
| Market Valuation (2033) | USD 1.1 billion |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to Future Market Insights, the global peptide synthesis market is predicted at a healthy 8% CAGR during the forecast period. Historically, the market registered a CAGR of 11.5% between 2017 and 2022.
The market is estimated to reach USD 1.1 billion during the forecast period. Historically, the market stood at USD 460.0 million from 2017 to 2022.
| Segments | Product and Services |
|---|---|
| Top Category | Reagents |
| Historic CAGR | 11.4% |
| Forecast CAGR | 7.8% |
| Segments | End Use |
|---|---|
| Top Category | Pharmaceuticals & Biotechnology Companies |
| Historic CAGR | 11.1% |
| Forecast CAGR | 7.6% |
Based on the product and services segment, the reagents category holds a maximum CAGR of 7.8% during the forecast period. The adoption of reagents widely in laboratories, pharmaceutical manufacturing, and research & development activities is driving the market growth.
Apart from reagents, coupling agents are also widely used by various chemical laboratories to identify or research a particular substance. These growing demand factors are flourishing the market expansion. Historically, the reagents captured a CAGR of 11.4% between 2017 and 2022.
Based on technology, the segment is divided into solid-phase peptide synthesis, solution-phase peptide synthesis, and membrane-enhanced peptide synthesis technology. Pharmaceuticals & biotechnology sectors use different technology to develop a certain product type. Therefore, chemical synthesis is the commonly used process for peptide production in these industries.
This process has influenced the adoption of enzymatic technology. Though, the changing environment and manufacturing caps on industries slow down the growth of this segment. The process of chemical synthesis triggers pollution and environmental risks.
Based on end use, there are several industries like CDMOs & CROs, pharmaceuticals & biotechnology, academics & research institutions, and others.
Pharmaceuticals and biotechnology are leading the segment by securing a CAGR of 7.6% during the forecast period. The adoption of peptide synthesis for the development of therapeutic in pharmaceuticals & biotechnology is bolstering the market growth.
The growing demand for drugs and vaccines with peptide synthesis is driving the pharmaceutical sector. For instance, AstraZeneca launched new advanced peptide therapy and next-generation medicine through research and development programs.
FDA-approved Rybelsus tablets for diabetes type 2 patients. Historically, pharmaceuticals & biotechnology secured a CAGR of 11.1% between 2017 and 2020.
| Countries | United States |
|---|---|
| CAGR (2017 to 2022) | 13.5% |
| CAGR (2023 to 2023) | 7.8% |
| Valuation (2023 to 2033) | USD 398.6 million |
| Countries | United Kingdom |
|---|---|
| CAGR (2017 to 2022) | 12.5% |
| CAGR (2023 to 2023) | 7.1% |
| Valuation (2023 to 2033) | USD 47.3 million |
| Countries | China |
|---|---|
| CAGR (2017 to 2022) | 13.1% |
| CAGR (2023 to 2023) | 7.4% |
| Valuation (2023 to 2033) | USD 80.7 million |
| Countries | Japan |
|---|---|
| CAGR (2017 to 2022) | 12% |
| CAGR (2023 to 2023) | 6.5% |
| Valuation (2023 to 2033) | USD 66 million |
| Countries | South Korea |
|---|---|
| CAGR (2017 to 2022) | 11.1% |
| CAGR (2023 to 2023) | 6% |
| Valuation (2023 to 2033) | USD 39.6 million |
The United States dominates the global market by securing a CAGR of 7.8% with a valuation of USD 398.6 million during the forecast period. The rise in chronic patients adopting peptide-based vaccines and drugs propels the United States market.
In 2022, according to the American Cancer Society, around 1.9 million new cancer cases grew in the United States. Cancer is a prior deadly disease after a heart attack in the United States.
Increasing rates of diabetes patients, inactive lifestyles, and obesity are fueling the United States peptide synthesis market. In addition, the development of modern drugs and increasing government investment are expanding the United States market. Historically, the United States secured a CAGR of 13.5% between 2017 and 2022.
The United Kingdom captured a CAGR of 7.1% with a valuation of USD 47.3 million during the forecast period. Developing advanced chemical and organic peptides with a high investment in research and development activities is expanding the United States market. In addition, the growing risk of chronic diseases and the presence of the biochemical industry is surging the United States peptide synthesis market.
The rising urbanization, healthcare infrastructure, and manufacturing industry are expanding the market. Historically, the United Kingdom secured a CAGR of 12.5% between 2017 and 2020.
China is contributing a CAGR of 7.4% with a valuation of USD 80.7 million during the forecast period. Increasing research and development investment and the biotech sector are flourishing in China's peptide synthesis market growth. In addition, rising demand for the minimal cost of raw materials and the adoption of advanced therapy is further increasing the China market expansion.
Lack of proper diet, a sedentary lifestyle, and low physical activities result in chronic diseases, increasing the demand for peptide synthesis. Moreover, the present prominent players and the development of new technologies in peptide synthesis are driving China market. Historically, China secured a CAGR of 13.1% between 2017 and 2020.
The multiple established companies and the presence of key players consolidate the market. In addition, due to the modernization of medical research and development projects and rising pharmaceutical manufacturing, the key competitors focus on providing effective products and services.
By adopting several marketing tactics and deep market research, the market players are increasing the sales of peptide synthesis products. Their marketing tactics are mergers, acquisitions, collaborations, and partnerships.
Recent Developments in the Market:
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD billion for Value |
| Key Countries Covered | United States, Canada, Germany, United Kingdom., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Northern Africa, South Africa, and Türkiye |
| Key Segments Covered | Product and Services, Technology, End Use, Region |
| Key Companies Profiled | GenScript Biotech Corporation; Bachem Holding AG; Thermo Fisher Scientific Inc; Merck KGaA; Kaneka Corporation |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market in 2023 is valued at US$ 520.0 million.
By 2033, the market will expand at a 8% CAGR.
By 2033, the market will reach US$ 1.1 billion.
From 2018 to 2022, the global market exhibited a 11.5% CAGR.
Merck KGaA, Kaneka Corporation
| Estimated Size, 2024 | USD 42.1 billion |
|---|---|
| Projected Size, 2034 | USD 117.4 billion |
| Value-based CAGR (2024 to 2034) | 10.8% |
Explore Life Science & Biotechnology Insights
View Reports
Peptide Synthesis Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
